This retrospective case series involved a review of medical records at a single tertiary care center. Charbel Issa and ...

The incidence of mild intraocular inflammation (IOI) in the real world occurs more frequently after intravitreal injection of ...

Berlin: Bayer has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval of ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

UNITY Biotechnology reveals promising 36-week results for UBX1325 in treating diabetic macular edema, showing non-inferiority ...

A potential game changer in the treatment of retinal disease, the novel dual-target drug shows encouraging results.

The trial assessed the efficacy of UBX1325, a treatment for diabetic macular edema (DME), and showed comparable vision gains to the current leading treatment, aflibercept. The results indicated ...

Biocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian ...